Akt pathway protein expression in gastrointestinal Kaposi sarcomas: relevance for tumor biology

Alina Badescu1, Anne Couvelard, Adriana Handra-Luca

  • 1APHP GHU Avicenne, Universite Paris Nord Sorbonne Cite, Bobigny, Romania; Universitatea de Medicina, Craiova, Romania.

Insights

This study investigated the AKT signaling pathway in gastrointestinal Kaposi sarcoma (KS). Researchers found that specific proteins in this pathway correlate with disease characteristics, suggesting potential therapeutic targets for KS treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Virology

Background:

  • Gastrointestinal Kaposi sarcoma (KS) is a rare manifestation of KS.
  • The AKT signaling pathway is implicated in KS pathogenesis, involving G protein-coupled receptors and KSHV/HHV8.
  • Rapamycin's potential in KS treatment, particularly in HIV patients, is under investigation due to its action on the AKT pathway.

Purpose of the Study:

  • To investigate the expression patterns of AKT pathway proteins in gastrointestinal KS.
  • To correlate protein expression with clinicomorphological features of the disease.

Main Methods:

  • Immunohistochemistry was used to assess the expression of AKT, 4EBP1, PTEN, and mTOR.
  • Expression levels were analyzed in tumor spindle cells and intratumor stromal vascular endothelial cells from 19 gastrointestinal KS biopsies.
  • Correlations with clinicomorphological features such as extravasated erythrocytes and hemosiderin were examined.

Main Results:

  • Tumor AKT expression correlated with a lack of extravasated erythrocytes.
  • Tumor PTEN expression correlated with the presence of intratumor hemosiderin.
  • Endothelial PTEN and low endothelial mTOR were associated with extravasated erythrocytes and hemosiderin.
  • High tumor 4EBP1 expression was linked to a high slit-type abnormal vascular component.

Conclusions:

  • The study suggests potential pro-permeability or pro-angiogenic roles for 4EBP1 and PTEN in KS.
  • Conversely, AKT and mTOR may have opposing roles in KS development.
  • These findings provide hypotheses for further research into KS pathogenesis and treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Tumor Progression02:07

Tumor Progression

3.2K